United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Can High Tide’s Remexian acquisition turn it into a global cannabis leader? €26.4m deal explained High Tide acquires 51% of Germany's Remexian Pharma for €26.4M with a 5-year full buyout option. Find out how this move expands its global cannabis reach. byPallavi MadhirajuSeptember 2, 2025